Patient Characteristics and Outcomes of Relapsed/ Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Oncology research and treatment, Erscheinungsjahr: 2020, Jahrgang: 43, Heft: 9, Seiten: 449-459, ISSN: 2296-5270
- Event
-
Veröffentlichung
- (where)
-
Leipzig
- (who)
-
Universitätsbibliothek Leipzig
- (when)
-
2023
- Creator
-
Steinmetz, H. Tilmann
Singh, Moushmi
Lebioda, Andrea
Gonzalez-McQuire, Sebastian
Rieth, Achim
Schoehl, Martina
Poenisch, Wolfram
- URN
-
urn:nbn:de:bsz:15-qucosa2-836451
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:42 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Steinmetz, H. Tilmann
- Singh, Moushmi
- Lebioda, Andrea
- Gonzalez-McQuire, Sebastian
- Rieth, Achim
- Schoehl, Martina
- Poenisch, Wolfram
- Universitätsbibliothek Leipzig
Time of origin
- 2023
Other Objects (12)
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma